

Author: Seliger Barbara
Publisher: Springer Publishing Company
ISSN: 0340-7004
Source: Cancer Immunology, Immunotherapy, Vol.57, Iss.11, 2008-11, pp. : 1719-1726
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Related content


Immunotherapy of MHC class I-deficient tumors
By Reiniš Milan
Future Oncology, Vol. 6, Iss. 10, 2010-10 ,pp. :






Oncology Reports, Vol. 28, Iss. 5, 2012-01 ,pp. :